title: Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
abstract: OBJECTIVE
  The aim of this study was to evaluate the economic impact of the introduction of positron emission tomography (PET) in the clinical management of patients with known or suspected lung cancer through a cost-effectiveness analysis of different diagnostic strategies.
  
  
  METHODS
  In Italy, 75 patients with known or suspected lung cancer were included in the study. Three different diagnostic strategies were compared: 1) baseline or traditional strategy, i.e. computed tomography (CT) alone; 2) strategy A, i.e. PET for indefinite CT; 3) strategy B, i.e. PET for all. For each strategy expected costs and life expectancy, as measured by life year saved (LYS), were evaluated. Incremental cost-effectiveness ratio (ICER) was calculated to identify the most effective strategy.
  
  
  RESULTS
  Compared to the baseline strategy, the introduction of PET changed the clinical management in 40% of cases in strategy A and in 51% of cases in strategy B, with an optimization of the clinical management. Costs of strategy A (2735.42 Euro) and strategy B (2984.52 Euro) were, respectively, 8% and 18% higher than the baseline strategy (2534.81 Euro). LYS was 2.04 and 2.64 for strategy A and B, which were, respectively, 4% and 35% higher than the baseline strategy (1.96 LYS). The ICERs were 2507.63 Euro/LYS and 415.17 Euro/LYS for strategy A and B, respectively. Strategy A is dominated by strategy B, which is more expensive, but also more effective.
  
  
  CONCLUSIONS
  In Italy, the introduction of PET in the clinical management of all patients with known or suspected lung cancer previously evaluated with CT is cost-effective and allows to gain 2.64 life years at an annual cost of about 415 Euro.
authors.affiliation: IBFM-CNR, University of Milano-Bicocca and Scientific Institute H San Raffaele, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Mansueto
authors.forename: A
authors.initials: A
authors.lastname: Grimaldi
authors.forename: A
authors.initials: A
authors.lastname: Torbica
authors.forename: G
authors.initials: G
authors.lastname: Pepe
authors.forename: G
authors.initials: G
authors.lastname: Giovacchini
authors.forename: C
authors.initials: C
authors.lastname: Messa
authors.forename: F
authors.initials: F
authors.lastname: Fazio
mesh_terms: D003362:Cost-Benefit Analysis / Q000191:economics / Q000706:statistics & numerical data; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000191:economics*; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000401:mortality; D008297:Male; D049268:Positron-Emission Tomography / Q000191:economics* / Q000706:statistics & numerical data; D019275:Radiopharmaceuticals / Q000191:economics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000191:economics* / Q000706:statistics & numerical data
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18